Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

FactSet Research: Strong Earnings Fail to Convince Skeptical Analyst

Dieter Jaworski by Dieter Jaworski
January 14, 2026
in Analysis, S&P 500, Tech & Software
0
FactSet Research Stock
0
SHARES
11
VIEWS
Share on FacebookShare on Twitter

A prominent analyst at Wells Fargo has reaffirmed a cautious stance on FactSet Research Systems Inc. (FDS), even after modestly raising the price target for the financial data provider’s shares. This adjustment follows a robust quarterly earnings report and a new capital return initiative, yet the bank’s outlook suggests the stock remains overvalued at current trading levels.

Analyst Maintains Bearish Rating Despite Target Hike

Wells Fargo increased its price objective for FactSet from $260 to $265 per share. However, the firm simultaneously confirmed its “Underweight” rating on the equity. This assessment indicates the analyst continues to see significant downside risk, as the stock has recently been trading well above this revised target.

Q1 2026 Performance Exceeds Expectations

The analyst’s update comes in response to FactSet’s strong results for its first fiscal quarter of 2026, which ended November 30, 2025. The company outperformed market forecasts on key metrics. Adjusted earnings per share (EPS) came in at $4.51, surpassing the consensus estimate of $4.36. Revenue showed a year-over-year increase of 6.9%, reaching $607.6 million and also beating projections.

Should investors sell immediately? Or is it worth buying FactSet Research?

Management provided guidance for the full 2026 fiscal year, forecasting EPS in the range of $16.90 to $17.60. This outlook aligns closely with the current market consensus of $17.21.

Conflicting Corporate Signals Emerge

Beyond the headline financial figures, several company-specific developments present a mixed picture for investors:

  • Expanded Share Buybacks: FactSet’s board of directors authorized an additional $600 million for share repurchases. Such programs are typically viewed as a signal of confidence in the company’s future cash flow generation.
  • Insider Selling Activity: Coinciding with the buyback announcement, a director engaged in share sales. Laurie Siegel exercised options and sold the resulting shares in early January 2026 at prices around $296. Transactions of this nature may be executed under a pre-arranged 10b5-1 trading plan, which allows insiders to trade according to a fixed schedule, though this is not always the case.
  • Prevailing Analyst Sentiment: The overall consensus rating for FactSet remains cautious, categorized as “Reduce.” The current breakdown of analyst recommendations includes 1 Strong Buy, 1 Buy, 10 Hold, and 5 Sell ratings.

FactSet shares currently trade at a price-to-earnings (P/E) ratio of approximately 18.9 and offer a dividend yield of 1.46%. The divergence between the firm’s solid operational performance and the restrained valuations from certain institutional analysts highlights the ongoing debate regarding the appropriate market value for this financial technology company. The upcoming quarterly results are expected to provide further clarity on the sustainability of its growth trajectory.

Ad

FactSet Research Stock: Buy or Sell?! New FactSet Research Analysis from February 8 delivers the answer:

The latest FactSet Research figures speak for themselves: Urgent action needed for FactSet Research investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 8.

FactSet Research: Buy or sell? Read more here...

Tags: FactSet Research
Dieter Jaworski

Dieter Jaworski

About Dieter Jaworski From a numbers-obsessed child to creating his first investment newsletter. Even as a child, Dieter Jaworski's mother couldn't believe how fascinated he was with numbers. This early passion for mathematics and data analysis laid the foundation for a successful career in financial markets and investment analysis.
Areas of Expertise:
  • Quantitative Analysis
  • Financial Newsletter Publishing
  • Data-Driven Investment Strategies
  • Market Pattern Recognition
Dieter's unique approach combines his natural affinity for numbers with decades of market experience, providing investors with data-driven insights and practical investment strategies.

Related Posts

DroneShield Stock
Analysis

DroneShield Shares Face Headwinds Despite Record Performance

February 8, 2026
Rock Tech Lithium Stock
Analysis

Rock Tech Lithium: Investors Await the Final Go-Ahead

February 8, 2026
Quanterix Stock
Analysis

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Next Post
Parker-Hannifin Stock

Parker-Hannifin Shares Attract Bullish Price Target Revisions

NetApp Stock

Goldman Sachs Initiates Coverage on NetApp with Bullish Outlook

Almonty Stock

Almonty Industries Enters New Phase Following Monumental Share Price Surge

Recommended

Cardano Stock

Cardano at a Crossroads: Navigating Critical Support Levels Amid Major Developments

3 months ago
Tesla Stock

Tesla Stock: Musk’s $30B Payday Amid Customer Exodus

6 months ago
Oxford Lane Capital Stock

Oxford Lane Capital Implements Strategic Overhaul with Reverse Split and Buybacks

5 months ago
Ciena Stock

Ciena Shares Hit Record Peak Amid AI Infrastructure Surge

5 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Repay Holdings: Annual Report to Test Strategic Refinancing Success

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Trending

DroneShield Stock
Analysis

DroneShield Shares Face Headwinds Despite Record Performance

by Jackson Burston
February 8, 2026
0

A significant disconnect has emerged for DroneShield Ltd. The counter-drone technology company posted explosive growth for fiscal...

Rock Tech Lithium Stock

Rock Tech Lithium: Investors Await the Final Go-Ahead

February 8, 2026
Puma Biotechnology Stock

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

February 8, 2026
Quanterix Stock

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Design Therapeutics Stock

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • DroneShield Shares Face Headwinds Despite Record Performance
  • Rock Tech Lithium: Investors Await the Final Go-Ahead
  • Puma Biotechnology Sets Date for Full-Year Financial Disclosure

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com